Pfizer Inc. (PFE) — closed signal from December 15, 2025
Partial Published before the outcome was known, scored automatically when the window closed on March 15, 2026 — +1% at the close.
Predicted vs. what happened
What happened
Reached 44% of the predicted growth at its peak, without hitting the target.
The thesis — published December 15, 2025
Pfizer looks like a safer, steady pharma company that suddenly saw a surge of buying. A licensing deal announced 12/15 with Adaptive could bring payments near $890M and meaningfully widen what Pfizer can develop. The buying looks strong right now, but underlying business metrics are weak, so treat this as a short-term trade and keep tight limits on losses.
Primary drivers
- Licensing deals could bring up to about $890M and broaden the pipeline
- Sudden buying interest with lots more buyers than usual supports the move
- Stable pharmaceutical business may attract money when markets are risky
- Rally driven by headlines despite weak fundamentals increases reversal risk
How it played out
PFE: target not reached inside the window
Lyra published PFE at $26.32 on 2025-12-15 with a short-term thesis for 14% expected growth. The thesis pointed to licensing deals worth up to about $890M, stronger than usual buying interest, a stable pharmaceutical business, and reversal risk because the rally depended on headlines while fundamentals looked weak.
Inside the window, PFE rose but did not reach $30. The peak was $27.94 on 2026-02-11, a 6.2% gain. It ended at $26.58 on 2026-03-15. The thesis partially played out because the stock moved up, but the published target was missed. It never got there.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.